The concept of neoplasia as a caricature of the process of tissue renewal was initially proposed by Pierce et al. (1978) who demonstrated in animal tumours that terminal differentiation occurs spontaneously and can be induced in several transplantable animal tumours (Pierce & Wallace, 1971 ; Wylie et al., 1972) . It had long been suspected that this might also be true of human tumours (Steel, 1977) , but until the development of the in vitro clonogenic assay, there was little direct evidence to support this concept. Studies of human ovarian carcinoma using a soft agar colony assay demonstrated that only a small proportion of the total tumour cell population is capable of forming colonies in culture . Subsequent studies of human urothelium showed similarities between the clonogenic cells of transitional cell carcinomas and the stem cells of the corresponding normal tissue and that morphologically differentiated, non-proliferative cells are numerous in the well differentiated tumours . These data suggest that terminal differentiation occurs in human transitional cell carcinoma, but the lack of appropriate markers of differentiation makes it difficult to demonstrate that the loss of proliferative potential is linked to the acquisition of features of differentiation. To overcome this difficulty, we have used hybridoma technology (Kohler & Milstein, 1975) to develop a panel of monoclonal antibodies against human transitional cell carcinoma in an attempt to identify markers of differentiation which could be used to study the cellular heterogeneity of human bladder cancer. Fresh human tissue was used for immunizations and for both primary and secondary screening. Tumour cell lines have not been studied because these may be poor models of primary human tumours (Mackillop et al., 1983 
Membrane preparations
The procedure for the production of membrane preparations has previously been described by Bates et al. (1985) .
Immunization
The method used for immunization is essentially as described by Major et al. (1987) (Shulman et al., 1978) and the method of hybrid selection have been described previously by Major et al. (1987) .
Screening of hybridoma supernatants ELISA Initial screening of hybridoma supernantants was performed using an enzyme-linked immunosorbent assay (ELISA) as described previously (Major et al., 1987) . All supernatants were screened against the membrane TCC preparation used for the final boost and against a preparation from normal human liver.
Avidin/Biotin immunoperoxidase staining Five-micron frozen and paraffin tissue sections were cut and mounted on gelatin-coated (Tissue Grip, Fisher) and glue-coated glass microscope slides, respectively. Secondary screening of monoclonal antibody supernatants was done using the avidin/biotin immunoperoxidase staining technique as described by Hsu et al. (1981) . Control sections were labelled with P3 (Horibata & Harris, 1970) 
Indirect immunofluorescence
Cell suspensions were prepared mechanically, as described previously . One million cells were suspended in 100pl monoclonal antibody supernatant and incubated at 4"C for 30min. Three millilitres of cold alpha-minimal essential medium (Gibco, Burlington, Ontario), supplemented with 10% foetal calf serum (Gibco) and 1% penicillin-streptomycin (30 IU ml -I and 30 pg ml -; Flow Laboratories, Mississuaga, Ontario), were added and the samples were centrifuged for 5min at 800g. This washing step was repeated twice. The cells were then resuspended in 100 pl fluorescein-conjugated f(ab')2 fragment goat antimouse IgM (Cooper Biomedical, West Chester, Pa.), and incubated at 4°C for 30 min. The cells were washed, and resuspended in PBS for flow cytometry. Control samples were labelled with an irrelevant primary antibody; P3 as an IgG negative control, and BN18 (Sullivan et al., 1986) , a mouse monoclonal antibody raised against rat myeloblasts, as an IgM negative control.
Flow cytometry
Single-cell suspensions were analysed using a fluorescenceactivated cell sorter (FACS-I1I; Becton-Dickinson, Mountain View, Ca.) linked to a custom-built microcomputer capable of displaying three-parameter data in real time . Fluorescence intensity was measured between 530 and 560 nm for all samples, using an excitation wavelength of 488 nm. The data were displayed as frequency distributions based on the analysis of 50,000 cells. Fluorescence intensity measurements were standardized as described previously (Ward et al., 1986) .
Results

Production of hybridomas
The hybridomas produced from two fusions have been screened and their tissue reactivity characterized. The first fusion produced 85 hybridomas, of which 59 were eliminated due to cross-reactivity with normal liver during the preliminary screening using ELISA. The second fusion resulted in 60 hybridomas, of which 50 were likewise eliminated. The remaining 36 antibodies were then tested against a wide range of normal and neoplastic human frozen tissue sections using the avidin/biotin immunoperoxidase staining technique. Thirty-three MoAbs showed varying degrees of cross-reactivity with other epithelia and were not studied further. Three MoAbs however, initially showed a degree of urothelial specificity and were selected for detailed study on multiple samples of normal and neoplastic human tissue.
Characteristics and specificities of monoclonal antibodies The specificities of the three monoclonal antibodies were initially established using frozen tissue sections.
MoAb 35.48 (IgG,k) was positive on all 6 normal urothelia (Table I ) and on 10 of 12 well and moderately differentiated TCCs (grades I and II), but on only 4 of 8 poorly differentiated TCCs (grades III). The diffuse staining (Tables I, II and III) . There was a marked preferential binding to the basal layer of some normal urothelial specimens, as shown in Panel E of Figure 1 ; this binding pattern was also prevalent on a number of other normal epithelia (Table II) . A similar pattern was observed in a few of the well differentiated papillary TCCs (Panel F, Figure 1 ).
MoAb 5.48 (IgM,k) was positive on all normal urothelial specimens tested (Table I) and on 5 of 6 there was preferential staining of the superficial cell layers (Panel C, Figure 1 ). Staining was most intense along the luminal surface of the superficial layer. Sixteen of 20 TCCs were also positive and in three papillary tumours there was similar preferential staining of the superficial layers (Panel D, Figure  1 ). There was cross-reactivity with other normal tissues and a few of the unrelated tumours were positive (Tables II and  III) aThe scoring system is as described in Table I ; s>b preferential staining of the superficial layers and b >s preferential staining of the basal layers.
of differentiated cells in skin and along the length of the digestive tract mucosa (Table V) . Quantitative studies were carried out using the fluorescence-activated cell sorter (FACS-III). MoAb 5.48 was tested on single-cell suspensions derived from specimens of normal urothelium and a group of TCCs. Figure 2 illustrates the frequency distributions of fluorescence intensity of MoAb 5.48 and the corresponding control samples for specimens of normal urothelium, well differentiated TCC, and poorly differentiated TCC. Approximately 95% of all cells in the control suspensions had a fluorescence intensity of less than 32 fluorescence units. This level of fluorescence was therefore arbitrarily chosen as the discriminator between labelled and unlabelled cells. MoAb 5.48 binds to all three samples (Figure 2 ), but by using this definition of positivity (see Figure 2) , a quantitative analysis can be made of the net percentage of positive cells (Table VI) . The percentage of positive cells is greater in the normal urothelia (P < 0.05) and well differentiated TCCs (P= 0.05), than in the poorly differentiated tumours (Table VI) .
MoAbs 35.48 and 21.48 have also been studied using the FACS, but all samples studied have been negative. Further evaluation with the fluorescent microscope confirmed that these MoAbs do not bind to inact cells, indicating that the antigens are not present on the cell surface.
Discussion
The urothelium is a self-renewing tissue in which differentiated cells are slowly lost from the luminal surface and replaced by the processes of proliferation, migration and differentiation of cells from the basal layer (Martin, 1962 (Martin, , 1967 Walker, 1959) . The preferential binding of MoAb 5.48 to the superficial cell layers of normal urothelium suggests that it binds to a cell-surface antigen which is acquired or exposed during the process of urothelial cell differentiation. MoAb 21.48, on the other hand, binds intracellularly to a site which is common to several types of epithelia but is lost as the cells migrate from the basal layer and acquire differentiated features. The observation that monoclonal antibodies 5.48 and 21.48 bind to well differentiated TCCs with a pattern similar to the normal urothelium supports the concept that cellular differentiation occurs in neoplastic tissue as it does in normal tissue. We have previously shown that the majority of cells in well differentiated human TCCs are morphologically differentiated, but that only a subpopulation of undifferentiated cells is capable of forming Figure 2) ; the number of cells with 32 or more units of fluorescence was determined and expressed as a percentage of the total. P values were determined using the Wilcoxon rank sum test and bMean + s.d. colonies in vitro . We now intend to use MoAbs 5.48 and 21.48 to isolate urothelial tumour subpopulations and investigate the relationship between cellular differentiation and proliferative potential in these tumours.
Several groups have produced monoclonal antibodies by immunization with bladder tumour cell lines. Some of these initially appeared to be tumour-specific (Koho et al., 1984; Grossman, 1983) or urothelial tumour-specific (Trejdosiewicz et al., 1985) when tested against a panel of cell lines, but have not been further characterized using primary human material. Other antibodies produced against bladder tumour cell lines, which have been at least partially characterized using human tissue, also appear to be tumour-specific (Masuko et al., 1984; Ben-Aissa et al., 1985) , or urothelial tumour-specific (Sasaki, 1984 , Messing et al., 1984 BenAissa et al., 1985) . Two groups have produced antibodies against human tumour cell lines which appear to be relatively specific for high grade urothelial tumours (Fradet et al., 1986; Young et al., 1985) .
Other groups have immunized with primary human tumours as opposed to cell lines. One such antibody (OmS), described by Fradet et al. (1984) appears to bind homogeneously and specifically to low grade TCCs in the same way as our antibody 35.48. Fradet also described two antibodies which, like our 21.48, demonstrated preferential binding to the basal layer of multiple normal epithelia. Summerhayes et al. (1985) previously reported on a family of monoclonal antibodies, also produced by immunization with fresh human tumours, which show specificity for different subpopulations of normal urothelial cells. Four of these antibodies resemble our antibody 5.48 and these antibodies show preferential binding to the luminal surface of the superficial cells of normal urothelium. Many patients with early stage bladder cancer can be managed conventionally by transurethral resection but a significant proportion will ultimately develop recurrences which are more invasive and may lead to death despite aggressive surgical or radiotherapeutic intervention at that time (Whitmore, 1979) . Tumour grade is a powerful prognostic factor in transitional cell carcinoma of the urinary bladder (Barnes et al., 1977) , but conventional histology does not adequately predict the natural history of this disease. It is possible that the use of differentiationspecific monoclonal antibodies may refine our ability to predict the behaviour of this tumour and permit urologic oncologists to define the subgroup of patients with early stage disease which requires early aggressive management for cure. Supported 
